|1.||Castaldo, Linda: 2 articles (01/2006 - 08/2005)|
|2.||Kaye, Stan B: 1 article (02/2013)|
|3.||Brock, Katie: 1 article (02/2013)|
|4.||Camidge, D Ross: 1 article (02/2013)|
|5.||Lal, Rohit: 1 article (02/2013)|
|6.||Spratlin, Jennifer L: 1 article (02/2013)|
|7.||Serkova, Natalie J: 1 article (02/2013)|
|8.||Demetri, George: 1 article (02/2013)|
|9.||Chick, Jon: 1 article (02/2013)|
|10.||Stephens, Andrew: 1 article (02/2013)|
02/15/2013 - "A phase I trial was undertaken to determine safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and antitumor activity of OSI-930 in patients with advanced solid tumors. "
03/01/2011 - "However, following discontinuation of OSI-930 administration tumor regrowth could be slowed by OXA-01 treatment. "
01/15/2006 - "We have investigated the relationships between the potency observed in cell-based assays in vitro, the plasma exposure levels achieved following oral dosing, the time course of target inhibition in vivo, and antitumor activity of OSI-930 in tumor xenograft models. "
09/15/2012 - "OSI-930, a dual c-Kit and KDR tyrosine kinase inhibitor, is reported to have undergone a Phase I dose escalation study in patients with advanced solid tumors. "
01/01/2009 - "Through LC/MS/MS, we show the CYP-mediated oxidative displacement of the trifluoromethoxy group from the phenyl constituent in OSI-930, a novel small molecule c-Kit/VEGF-r inhibitor in clinical studies to treat cancer. "
|2.||Mast-Cell Leukemia (Leukemia, Mast Cell)
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|3.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|6.||glucuronyl glucosamine glycan sulfate (Vessel)
|1.||Heterologous Transplantation (Xenotransplantation)